It could have been clearer in the News story ‘Ebola R&D woes spur action’ (Nature 521, 405–406; 2015) that the US Food and Drug Administration was not consulted about or involved in the design of the brincidofovir study; the agency advocated generally for randomized clinical trials on drugs against Ebola. In the News Feature ‘CRISPR, the disruptor’ (Nature 522, 20–24; 2015), the June 2012 entry in the graphic entitled ‘The rise of CRISPR’ was ambiguous. The researchers had targeted the CRISPR system to specific DNA sequences, highlighting its potential for genome editing.
Additional information
The online version of the original article can be found at 10.1038/521405a
The online version of the original article can be found at 10.1038/522020a
Related links
Related links
Related links in Nature Research
Related external links
Rights and permissions
About this article
Cite this article
Correction: Clarifications. Nature 522, 141 (2015). https://doi.org/10.1038/522141a
Published:
Issue Date:
DOI: https://doi.org/10.1038/522141a
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.